Tegavivint for kids and young adults with hard-to-treat solid tumors
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Genetic & congenital, Hormones & metabolism, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 1 month to 21 years old for the main group, or up to 30 years old for specific tumor groups
- Your cancer is a solid tumor that has returned or is resistant to treatment (includes certain lymphomas and desmoid tumors)
- Your cancer was confirmed by a tissue biopsy, and you have measurable disease (desmoid must be judged not safe to remove)
- You must be well enough to do daily activities: performance score must be 0, 1, or 2 (based on age-appropriate scales)
- You must have recovered from prior cancer treatment, with a required waiting time and no prior tegavivint exposure
- Blood and organ tests must be within required ranges (including bone marrow functioning depending on whether it’s involved)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This study tests a new cancer drug called Becotatug Vedotin in children ages 2–18 with certain types of solid tumors (cancers that form in organs or tissues) that have an EGFR protein. The drug is designed to find tumors with this protein and attack cancer cells while sparing healthy ones.
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
This Phase 1 trial tests tegavivint, a new investigational medicine, for certain types of aggressive B-cell lymphoma that have come back or did not respond to prior treatment. It may help shrink the lymphoma and learn how safe and effective the drug is in this setting.
This early-phase trial tests an experimental drug called tegavivint for people with advanced colorectal cancer who have already tried several standard treatments. It aims to see if the drug can shrink or slow the growth of tumors.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.